Diazepam Promotes Translocation of Human Constitutive Androstane Receptor (CAR) via Direct Interaction with the Ligand-Binding Domain.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
24 11 2020
Historique:
received: 17 08 2020
revised: 07 10 2020
accepted: 20 11 2020
entrez: 1 12 2020
pubmed: 2 12 2020
medline: 23 6 2021
Statut: epublish

Résumé

The constitutive androstane receptor (CAR) is the essential regulator of genes involved both in xenobiotic and endobiotic metabolism. Diazepam has been shown as a potent stimulator of CAR nuclear translocation and is assumed as an indirect CAR activator not interacting with the CAR cavity. In this study, we sought to determine if diazepam is a ligand directly interacting with the CAR ligand binding domain (LBD) and if it regulates its target genes in a therapeutically relevant concentration. We used different CAR constructs in translocation and luciferase reporter assays, recombinant CAR-LBD in a TR-FRET assay, and target genes induction studied in primary human hepatocytes (PHHs), HepaRG cells, and in CAR humanized mice. We also used in silico docking and CAR-LBD mutants to characterize the interaction of diazepam and its metabolites with the CAR cavity. Diazepam and its metabolites such as nordazepam, temazepam, and oxazepam are activators of CAR+Ala in translocation and two-hybrid assays and fit the CAR cavity in docking experiments. In gene reporter assays with CAR3 and in the TR-FRET assay, only diazepam significantly interacts with CAR-LBD. Diazepam also promotes up-regulation of CYP2B6 in PHHs and in HepaRG cells. However, in humanized CAR mice, diazepam significantly induces neither

Identifiants

pubmed: 33255185
pii: cells9122532
doi: 10.3390/cells9122532
pmc: PMC7761063
pii:
doi:

Substances chimiques

Constitutive Androstane Receptor 0
Ligands 0
NR1I3 protein, human 0
Nr1i3 protein, mouse 0
Receptors, Cytoplasmic and Nuclear 0
Diazepam Q3JTX2Q7TU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Clin Invest. 2008 Sep;118(9):3228-39
pubmed: 18677425
Mol Cell Biol. 1999 Sep;19(9):6318-22
pubmed: 10454578
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Methods Mol Biol. 2006;320:283-93
pubmed: 16719400
J Pharm Sci. 1973 Nov;62(11):1789-96
pubmed: 4758075
Mol Pharmacol. 2011 Sep;80(3):518-28
pubmed: 21628639
Sensors (Basel). 2015 Apr 21;15(4):9265-76
pubmed: 25905697
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Toxicol Lett. 2010 Mar 15;193(2):183-8
pubmed: 20080160
Toxicol Sci. 2011 Oct;123(2):550-62
pubmed: 21778469
Mol Cell. 2004 Dec 22;16(6):919-28
pubmed: 15610735
Toxicol Sci. 2010 Aug;116(2):452-66
pubmed: 20403969
Sci Signal. 2013 May 07;6(274):ra31
pubmed: 23652203
Drug Metab Dispos. 2009 May;37(5):1098-106
pubmed: 19196842
Xenobiotica. 1996 Nov;26(11):1155-66
pubmed: 8948091
Drug Metab Dispos. 2018 Sep;46(9):1361-1371
pubmed: 29759961
J Hepatol. 2016 Jul;65(1):66-74
pubmed: 26948495
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Drug Metab Dispos. 2001 Mar;29(3):242-51
pubmed: 11181490
Mol Cell Biol. 1998 Oct;18(10):5652-8
pubmed: 9742082
Biochim Biophys Acta. 2016 Sep;1859(9):1130-1140
pubmed: 26877237
Toxicol Res (Camb). 2018 Mar 12;7(4):697-717
pubmed: 30090615
Curr Drug Metab. 2019;20(1):29-35
pubmed: 30227815
Sci Rep. 2015 May 20;5:10405
pubmed: 25993555
Drug Metab Rev. 2006;38(1-2):235-59
pubmed: 16684660
Arch Toxicol. 2019 Aug;93(8):2247-2264
pubmed: 31312845
Acta Pharm Sin B. 2016 Sep;6(5):413-425
pubmed: 27709010
Toxicology. 2018 Mar 1;396-397:23-32
pubmed: 29425889
Biochem Pharmacol. 1998 May 15;55(10):1633-40
pubmed: 9633999
Biochim Biophys Acta. 2007 Jun;1773(6):934-44
pubmed: 17488649
Mol Pharmacol. 2008 Aug;74(2):443-53
pubmed: 18492798
J Chem Inf Model. 2011 Oct 24;51(10):2778-86
pubmed: 21919503
Mol Pharmacol. 2002 Aug;62(2):359-65
pubmed: 12130689
J Pharmacol Exp Ther. 2010 Jan;332(1):106-15
pubmed: 19820207
Int J Mol Sci. 2018 Nov 24;19(12):
pubmed: 30477223
J Biol Chem. 2003 May 9;278(19):17277-83
pubmed: 12611900
Pharm Res. 2015 Feb;32(2):604-16
pubmed: 25163980

Auteurs

Josef Skoda (J)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Jan Dusek (J)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Martin Drastik (M)

Department of Physical Chemistry and Biophysics, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Alzbeta Stefela (A)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Klara Dohnalova (K)

1st Medical Faculty, Charles University, Katerinská 32, 121 08 Prague, Czech Republic.
Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic.

Karel Chalupsky (K)

Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic.

Tomas Smutny (T)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Stanislav Micuda (S)

Department of Pharmacology, Medical Faculty in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.

Sabine Gerbal-Chaloin (S)

IRMB, University of Montpellier, INSERM, 34295 Montpellier, France.

Petr Pavek (P)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH